The potential to receive up to $21M in future development and sales milestone payments, along with royalty rates ranging from 0.25% to 7%, presents a significant financial opportunity for Enveric Biosciences. This could positively impact the company's revenue and profitability in the short term, assuming the milestones are met and the royalties come into effect. The high relevance score is due to the direct mention and significant potential financial benefit to ENVB.